R&D Insights: How Biogen Inc. and CRISPR Therapeutics AG Allocate Funds

R&D Spending: A Tale of Two Innovators

In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Biogen Inc. and CRISPR Therapeutics AG, two giants in the biotech industry, have shown distinct approaches to R&D investment over the past decade.

Biogen Inc., a leader in neuroscience, has consistently allocated substantial resources to R&D, with expenditures peaking in 2020 at nearly double their 2014 levels. This reflects a robust commitment to advancing treatments for neurological disorders. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, has demonstrated a remarkable growth trajectory in R&D spending, increasing by over 25,000% from 2014 to 2023. This surge underscores their aggressive pursuit of cutting-edge genetic therapies.

These trends highlight the dynamic nature of biotech innovation, where strategic R&D investments can shape the future of healthcare.